Newly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutics, including a clinical-stage drug whose development has already spanned several companies and more than three decades.
Tag Archive for: startups
Swiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders.
French biotech Brenus Pharma has raised an €11 million Series A extension to complete the Phase 1 development of its lead colorectal cancer immunotherapy and advance a second programme from its platform.
Belgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis.
Kelli McClintock auf UnsplashTen young European biotechs are heading into 2026 with the kind of momentum that can quickly turn promising science into defining data: first clinical entries, platform-to-pipeline transitions, and funding rounds large enough to accelerate execution. Some are pushing new modalities into hard disease areas, while others are compressing discovery timelines and expanding what’s druggable. What they all share is a clear momentum that makes them especially worth following this year.
Paris-based kyron.bio has signed a strategic partnership with French pharma group Servier to glycoengineer an antibody selected by Servier. This agreement marks an early proof-of-concept deal designed to show the company can reliably “dial in” a specific, pre-defined N-glycoform on a therapeutic antibody.
Technologiepark HeidelbergThe Technologiepark Heidelberg has been shaping Heidelberg‘s startup ecosystem with 100,000 sqm of lab and office spaces, individual startup support, and top events for over 40 years – offering ideal conditions for established companys and startups in the fields of life sciences, biotech, industry tech, and AI.